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Abstract
Background: Metabolic syndrome (MetS) describes clustering of obesity, dyslipidemia, hyperglycemia and hypertension and increases 
risk for cardiovascular disease and type 2 diabetes. The ‘hypertriglyceridemic waist’ phenotype (HTGW) represents a simple approach to 
identifying individuals with increased risk. The aim of the study was to determine the prevalence of HTGW and MetS in type 2 diabetic 
patients, and to examine their relation to lipids and blood glucose control.
Material and methods: 300 type 2 diabetic patients were analysed, and their history of diabetes, anthropometric measures, measurements 
of blood pressure (BP), lipids and glycemic control parameters were taken.
Results: In type 2 diabetic patients, the prevalence of MetS was 71.0% by the AHA/NHLBI definition and 75.33% by the IDF definition. 
The prevalence was 62.58% and 66.45% in men, and 80% and 84.83% in women by the same definitions, respectively. There were 41.33% 
of patients with HTGW (42.76% among women and 40% among men). There were statistically significant differences of age, fasting plasma 
glucose (FPG) and postprandial glucose (PPG) in women with and without MetS according to both definitions, and of total and LDL 
cholesterol with and without MetS according to AHA/NHLBI (but not IDF). In men, there were statistically significant differences of total 
cholesterol and of HbA1c with and without MetS according to AHA/NHLBI (but not IDF). Women with HTGW had higher levels of total 
and LDL cholesterol, systolic and diastolic BP. Men with HTGW had higher levels of total cholesterol, diastolic BP, HbA1c, FPG and PPG.
Conclusions: Determining MetS or HTGW helps identify those with increased cardiovascular risk.  (Pol J Endocrinol 2011; 62 (4): 316–323)
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Streszczenie
Wstęp: Zespół metaboliczny (MetS) obejmujący otyłość, dyslipidemię, hiperglikemię i nadciśnienie tętnicze zwiększa ryzyko chorób 
sercowo-naczyniowych i cukrzycy typu 2. Określanie fenotypu „talii hipertriglicemicznej” (HTGW) jest prostą metodą identyfikowania 
chorych z grupy wysokiego ryzyka. Celem badania było ustalenie częstości HTGW i MetS u chorych na cukrzycę typu 2 oraz ocena za-
leżności miedzy tymi zaburzeniami a kontrolą stężeń lipidów i glikemii.
Materiał i metody: Do badania włączono 300 chorych na cukrzycę typu 2 i przeanalizowano dane dotyczące przebiegu cukrzycy, para-
metrów antropometrycznych, wartości ciśnienia tętniczego, stężeń lipidów i kontroli glikemii.
Wyniki: U chorych na cukrzycę typu 2 kryteria MetS według definicji AHA/NHLBI spełniało71,0%, a kryteria IDF — 75,33%; odsetek 
chorych z MetS wynosił wśród mężczyzn odpowiednio 62,58% i 66,45%, a wśród kobiet 80% i 84,83%. U 41,33% chorych stwierdzono cechy 
HTGW, 42,76% tej grupy stanowiły kobiety, a 40% mężczyźni. U kobiet wykazano istotne statystycznie różnice w zakresie wieku, glikemii 
na czczo (FPG) i glikemii poposiłkowej (PPG) między grupami z MetS i bez niego, rozpoznanym na podstawie obu definicji, natomiast 
w zakresie stężenia cholesterolu całkowitego i frakcji LDL różniły się one tylko między grupami z  MetS i bez niego wydzielonymi na pod-
stawie definicji AHA/NHLBI (a nie na podstawie kryteriów IDF). U mężczyzn wykazano statystycznie istotne różnice stężeń cholesterolu 
całkowitego HbA1c między grupami z MetS i bez niego określonym według AHA/NHLBI (ale nie według IDF). U kobiet z HTGW stwier-
dzono wyższe stężenia cholesterolu całkowitego i cholesterolu frakcji LDL oraz wyższe wartości ciśnienia skurczowego i rozkurczowego. 
U mężczyzn z HTGW odnotowano wyższe wartości stężeń cholesterolu całkowitego, rozkurczowego ciśnienia tętniczego, HbA1c, FPG i PPG.
Wnioski: Rozpoznanie MetS lub HTGW pozwala zidentyfikować osoby obciążone zwiększonym ryzykiem sercowo-naczyniowym.
(Endokrynol Pol 2011; 62 (4): 316–323)
Słowa kluczowe: talia hipertriglicemiczna, zespół metaboliczny, cukrzyca typu 2, profil lipidowy, kontrola glikemii
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Introduction
Metabolic syndrome (MetS) describes a constellation 
of clinical characteristics that are associated with an in-
creased risk of developing atherosclerotic cardiovascu-
lar disease (CVD) and type 2 diabetes (DM), including 
central obesity, glucose intolerance, hypertension, 
low HDL (high density lipoprotein) cholesterol, and 
elevated triglycerides. It has been demonstrated that 
individuals with MetS are at increased (2 to 3 times) 
risk of cardiovascular events, and a five times greater 
risk of diabetes [1, 2]. The underlying causes of MetS 
are considered to be central adiposity, insulin resistance, 
and genetic predisposition [2].
Since its initial description by Reaven in 1988, several 
definitions of MetS have emerged. The first global defi-
nition of MetS was by the World Health Organisation 
(WHO) in 1998, followed by the European Group for 
the Study of Insulin Resistance (EGIR) in 1999 [3, 4]. 
Two years later, in 2001, the USA’s National Cholesterol 
Education Program — Third Adult Treatment Panel 
(NCEP-ATP III) introduced the NCEP definition which 
assumes that MetS is a clinical utility by treating all its 
components as equally important and does not include 
a specific measure of insulin [5]. The NCEP definition 
became popular because of its simplicity and feasibility 
in that its components could be easily and routinely 
determined in most clinical and research settings. This 
definition was not only simple and practical but has 
also been shown to be superior in predicting CVD [6]. 
The American Heart Association/National Heart, Lung 
and Blood Institute Scientific Statement (AHA/NHLBI) 
revised the NCEP definition in 2005 [7].
In 2005, the International Diabetes Federation (IDF) 
proposed a definition of MetS similar to that of the 
NCEP, but with increased waist circumference (WC) 
as a necessary requirement, emphasising the central 
importance of abdominal obesity. The IDF has recom-
mended that the cut off points for waist circumference 
should be specific to an ethnic group [8].
The various MetS definitions include the same core 
criteria of central obesity, hyperglycaemia, dyslipidemia 
and high blood pressure, but differ in the cut-off points 
for individual criteria, in specific mandatory require-
ments (e.g. abdominal obesity or insulin resistance) and 
in the inclusion of additional factors (e.g. microalbu-
minuria). Hence, they identify broadly similar, but not 
identical, groups of individuals with MetS.
The criteria which are used for the definition of 
MetS based on the recommendations described above 
are shown in Table I.
It has been demonstrated by previous large scale 
studies that central obesity, as measured by WC, is 
closely related to coronary heart disease (CHD) risk 
[9,10]. Although there is accumulating evidence sup-
porting the significant role of WC in predicting CHD 
events, it has not been translated into an enhancement 
of predictability of the IDF criteria for MetS on the de-
velopment of CHD, given that in the IDF definition, WC 
is a required component for labelling individuals with 
MetS. On the contrary, studies have reported that MetS 
definitions have a similar ability to predict an incident 
Table I. Three definitions of metabolic syndrome
Tabela I. Trzy definicje zespołu metabolicznego
NCEP ATP III 2001, ref 5
At least three of the following:
AHA/NHLBI 2005, ref 7
At least three of the following:
IDF 2005, ref 8
Waist circumference (for subjects of 
European origin) ≥ 94 cm (men), ≥ 80 cm 
(women), plus any two of the following:
1. Fasting plasma glucose
 ≥ 6.1 mmol/l
1. Fasting plasma glucose
≥ 5.6 mmol/l or drug treatment for elevated 
glucose
1. Fasting plasma glucose 
≥ 5.6 mmol/l or known type 2 diabetes
2. Blood pressure 
≥ 130 mm Hg/≥ 85 mm Hg
2. Systolic BP ≥ 130 mm Hg or diastolic BP 
≥ 85 mm Hg or treatment for hypertension
2. Systolic BP ≥ 130 mm Hg 
and/or diastolic BP
≥ 85 mm Hg or treatment for hypertension
3. Triglycerides ≥ 1.7 mmol/l 3. Triglycerides ≥ 1.7 mmol/l or drug 
treatment for elevated triglycerides
3. Triglycerides ≥ 1.7 mmol/l or specific 
treatment
4. HDL-cholesterol 
< 1.03 mmol/l (men) or
< 1.29 mmol/l (women)
4. HDL-cholesterol 
< 1.03 mmol/l (men) or 
< 1.29 mmol/l (women) or drug treatment 
for low HDL-cholesterol
4. HDL-cholesterol 
< 1.03 mmol/l (men) or
< 1.29 mmol/l (women) or specific 
treatment
5. Waist circumference 
> 102 cm (men), > 88 cm (women)
5. Waist circumference 
≥ 102 cm (men), ≥ 88 cm (women)
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of CHD [11, 12]. The debate continues as to whether 
the metabolic syndrome is really a discrete syndrome 
adding predictive value over and above the sum of its 
components [13, 14].
Increasing evidence identifies factors other than 
ordinary lipid profile to be predictors of atheroscle-
rosis. Many studies performed on nontraditional 
risk factors have proposed a metabolic “triad” com-
prising increased serum level of apolipoprotein B, 
hyperinsulinaemia and high small, dense LDL (low 
density lipoprotein) cholesterol as a risk factor of 
cardiovascular diseases [15]. It is suggested that the 
simultaneous measurement and interpretation of 
waist circumference and fasting triglyceride con-
centration could be used as inexpensive screening 
tools to identify men characterised by the athero-
genic metabolic triad and at high risk for CHD. The 
“hypertriglyceridemic waist” phenotype (HTGW), 
consisting of a waist wider than 90 cm in men and 
85 cm in women, along with a plasma triglyceride 
concentration of 2.0 mmol/l or over, may be a simple 
screening approach for identifying individuals with 
increased cardiometabolic risk [16].
Whichever definition is used, large epidemio-
logical surveys show that MetS is common. The 
prevalence of MetS is increasing, in parallel with the 
ageing population and the “epidemic” of obesity, and 
its increasing prevalence could possibly reverse the 
gains made through recent declining CVD mortality. 
Strategies to combat the forecast epidemic of type 2 
diabetes and its vascular complications should focus 
on preventing and intervening early in metabolic 
syndrome [17].
The aim of this study was to determine the preva-
lence of the “hypertriglyceridemic waist” phenotype 
and the metabolic syndrome, using the most popular 
definitions, in type 2 diabetic patients, and to examine 
the relationship between ‘hypertriglyceridemic waist’ 
phenotype and the metabolic syndrome and blood 
lipids and blood glucose control in these patients.
Material and methods
300 subjects with type 2 diabetes who were consecu-
tively admitted to the Clinic for Endocrinology, Dia-
betes and Diseases of Metabolism, Clinical Centre Niš 
were included in this observational prospective study 
over a three-month period. None of these patients was 
excluded, so as to reflect the true clinical picture of the 
CVD risk profile in this patient cohort. 
All the data was gathered as part of the routine clini-
cal work up, and informed consent was obtained from 
all patients for all the procedures and to allow use of 
data for research purposes.
For each subject, the following data were collected 
as part of their routine clinical care: age, sex, diabetes 
duration, weight, height, body mass index (BMI), waist 
circumference (WC), blood pressure (BP), total choles-
terol, HDL cholesterol, LDL cholesterol, triglyceride, 
fasting plasma glucose (FPG), postprandial glucose 
(PPG) and glycated haemoglobin A1c (HbA1c).
Height, weight, and waist circumference were 
measured with the subject standing. Weight was 
measured while they were minimally clothed without 
shoes, using digital scales and recorded to the nearest 
100 g. Height was measured in a standing position 
without shoes, using a standard anthropometer. 
Body mass index was calculated as weight in kilo-
grams divided by height in metres squared. With the 
participant standing and breathing normally, waist 
circumference was measured midway between the 
superior iliac crest and the costal margin (at the level 
of the umbilicus), using a tape measure. Two blood 
pressures at five minute intervals were recorded after 
the subject had been seated for at least five minutes, 
and the arithmetic mean used in data analysis. Blood 
samples were obtained in the early morning after 
12 to 14 hours of overnight fasting for biochemical 
measurements. Blood samples were obtained from 
an antecubital vein while participants were sitting 
and centrifuged within 45 minutes of collection; all 
blood analyses being done at the Central Laboratory 
of the Clinical Centre Niš on the day of blood collec-
tion. Blood samples for PPG were obtained two hours 
after breakfast. FPG, PPG, total cholesterol, HDL 
cholesterol and triglycerides were measured by the 
standard enzymatic colorimetric method using com-
mercially available enzymatic reagents kits provided 
by Olympus; LDL cholesterol was calculated by the 
Friedewald formula, and HbA1c was measured by 
a standard immunochemistry method using reagents 
kits provided by Olympus. All parameters were meas-
ured on an Olympus AU 680 automatic analyser at 
the accredited university hospital laboratory in Niš.
MetS was defined according to each of the 
AHA/NHLBI [7] and IDF [8] definitions as described in 
Table 1. The main difference between the NCEP defini-
tion and the AHA/NHLBI definition is in terms of the 
hyperglycaemia criterion [5, 7]. Since our patients were 
diabetic, they fulfilled both these criteria simultaneously. 
The hypertriglyceridemic waist phenotype was defined 
as having both a high waist circumference (wider than 
90 cm in men and 85 cm in women) and increased fast-
ing triglyceride levels (2.0 mmol/l or over) [16].
Continuous variables were reported as mean ± stan-
dard deviation (SD) and categorical variables were 
reported as percentages. The c2 test was used for 
the comparison of categorical variables. Student’s 
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t-test was used for the comparison of continuous vari-
ables. P < 0.05 was considered as statistically significant. 
Results
Of the 300 T2DM patients, there were 145 women 
(48.33%) and 155 men (51.67%). Average duration of 
DM was 11.93 ± 8.21 years (12.35 ± 8.08 in women and 
11.54 ± 8.33 in men).
According to the AHA/NHLBI criteria, there were 
213 patients with MetS (71.0%); 116 of these were 
women (54.46%) and 97 men (45.54%), or 80% of the 
women (116 of 145) and 62.58% of the men (97 of 155). 
According to the IDF criteria, there were 226 patients 
with MetS (75.33%); 123 of these were women (54.42%) 
and 103 men (45.58%), or 84.83% of the women (123 of 
145) and 66.45% of the men (103 of 155). There were 124 
patients with HTGW (41.33%), 62 women (50%) and 
62 men (50%), or 42.76% of the women (62 of 145) and 
40% of the men (62 of 155). 
There were no significant differences in the preva-
lence of MetS according to AHA/NHLBI or IDF criteria, 
neither in the whole group of patients, nor in women or 
in men. There was a significantly higher prevalence of 
MetS in women than in men (when using both criteria). 
There were no significant differences in the prevalence of 
HTGW among women and men. There were significantly 
fewer patients with HTGW than with MetS, both in 
women and in men and with using both criteria for MetS.
Comparison of age and duration of DM in patients 
with and without MetS or HTGW, as well as parameters 
of blood glucose control and blood lipids, is shown in 
Tables II and III. Apart from differences in parameters 
comprising MetS (WC, blood pressure, HDL, triglycer-
ides), there were statistically significant differences of 
age, FPG and PPG in women with and without MetS 
according to both definitions and of total and LDL 
cholesterol with and without MetS according to the 
AHA/NHLBI definition (but not the IDF definition). 
In men there were statistically significant differences 
in parameters comprising MetS (WC, blood pressure, 
HDL, triglycerides), and of total cholesterol and of HbA1c 
with and without MetS according to the AHA/NHLBI 
definition (but not IDF definition). Women with HTGW 
have significantly higher levels of total and LDL choles-
terol, systolic and diastolic BP. Men with HTGW have 
Table II. Characteristics of 145 female subjects with type 2 diabetes classified according to the two definitions of metabolic 
syndrome and the “hypertriglyceridemic waist” phenotype
Tabela II. Charakterystyka 145 kobiet chorujących na cukrzycę typu 2 w grupach wydzielonych na podstawie dwóch definicji 
zespołu metabolicznego i fenotypu “talii hipertriglicemicznej”
AHA/NHLBI definition IDF definition “Hypertriglyceridemic waist”phenotype
Subjects MetS No MetS MetS No MetS HTGW No HTGW
No. (%) 116 (80) 29 (20) 123 (84.83) 22 (15.17) 62 (42.76) 83 (57.24)
Age (years) 62.34 ± 9.37* 58.17 ± 9.68 62.34 ± 9.21** 56.86 ± 10.25 61.85 ± 9.55 61.25 ± 9.59
Duration of DM 
(years) 12.38 ± 7.72 12.24 ± 9.56 12.20 ± 7.95 13.23 ± 8.93 12.06 ± 7.07 12.57 ± 8.80
BMI [kg/m2] 30.06 ± 4.20** 26.15 ± 4.28 29.87 ± 4.15** 25.97 ± 4.89 30.34 ± 3.69** 28.49 ± 4.86
WC [cm] 98.13 ± 8.64** 84.10 ± 11.06 97.42 ± 8.83** 83.59 ± 12.91 99.35 ± 6.54** 92.31 ± 12.20
SBP [mm Hg] 142.76 ± 20.01** 122.93 ± 16.34 141.83 ± 20.50** 121.82 ± 13.68 142.58 ± 19.87* 135.96 ± 21.25
DBP [mm Hg] 83.62 ± 10.25** 75.86 ± 8.67 83.09 ± 10.23** 76.36 ± 9.66 83.95 ± 10.17* 80.66 ± 10.41
TC [mmol/l] 6.09 ± 1.40** 5.37 ± 0.94 6.03 ± 1.41 5.47 ± 0.80 6.57 ± 1.21** 5.47 ± 1.26
HDL-C (mmol/l) 1.36 ± 0.37* 1.50 ± 0.23 1.36 ± 0.37** 1.55 ± 0.19 1.39 ± 0.42 1.40 ± 0.30
LDL-C [mmol/l] 3.69 ± 1.12** 3.13 ± 0.91 3.63 ± 1.16 3.31 ± 0.68 3.90 ± 1.03** 3.35 ± 1.10
TG [mmol/l] 2.32 ± 1.22** 1.15 ± 0.57 2.25 ± 1.22** 1.18 ± 0.63 3.06 ± 1.18** 1.35 ± 0.53
HbA1c (%) 8.21 ± 1.75 7.66 ± 2.30 8.15 ± 1.78 7.83 ± 2.39 8.29 ± 1.91 7.96 ± 1.85
FPG (mmol/l) 9.12 ± 3.12** 7.14 ± 3.70 8.97 ± 3.17* 7.37 ± 3.92 9.23 ± 3.09 8.35 ± 3.46
PPG (mmol/l) 12.97 ± 3.90** 10.91 ± 5.01 12.83 ± 4.01* 11.07 ± 5.01 13.30 ± 4.22* 12.01 ± 4.13
AHA/NHLBI — American Heart Association/National Heart, Lung and Blood Institute; IDF —  International Diabetes Federation; MetS — metabolic 
syndrome; HTGW — “hypertriglyceridemic waist”; BMI —  body mass index; WC — waist circumference; SBP — systolic blood pressure; 
DBP —  diastolic blood pressure; TC — total cholesterol; HDL-C — high density lipoprotein cholesterol; LDL-C —  low density lipoprotein cholesterol; 
TG —  triglyceride; HbA1c — glycated haemoglobin A1c; FPG —  fasting plasma glucose; PPG — postprandial glucose; Data are mean ± SD; 
*MetS vs. no MetS or HTGW vs. no HTGW p < 0.05; **MetS vs. no MetS or HTGW vs. no HTGW p < 0.01
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significantly higher levels of total cholesterol, diastolic 
BP, HbA1c, FPG and PPG.
Discussion
Data regarding the prevalence of MetS varies in dif-
ferent populations. In the general population, MetS 
is found in around one third of people. Using the US 
national data, and the definition of MetS proposed by 
the IDF, almost 40% of U.S. adults were classified as hav-
ing MetS, an estimate higher than that reached using 
the NCEP definition (34.5%). The prevalence of MetS 
in a high risk population is much higher. A study of 
a population of diabetic patients found the prevalence 
of MetS to be 72.1% (NCEP) and 84.4% (IDF) [18]. There 
is very great concordance between the two definitions 
in identifying MetS. In the abovementioned study, 
around 93% of patients were classified in the same way 
as having or not having MetS. In a Chinese population, 
agreement of the two definitions in the risk population 
of hypertensive patients was 94.4% in men and 97% in 
women. Almost one third of hypertensive men, and one 
half of hypertensive women, have MetS [19]. 
Our results, showing that almost three quarters of 
type 2 diabetic patients have MetS, are in accordance 
with this and other published results on the prevalence 
of MetS. They confirm the importance and magnitude 
of the problem of MetS, especially in high risk popula-
tions such as diabetic patients. Our results showed no 
differences in the number of patients with MetS when 
using both definitions. This high concordance of the two 
definitions is perhaps not surprising given that these 
definitions use almost identical variables, except for the 
central obesity criteria.
In our study, the prevalence of MetS was higher in 
women than in men (defined by both definitions). Pub-
lished data on the prevalence of MetS differs: in Western 
societies, MetS is more common in men than in women 
[18, 20], but in Chinese and Arab populations it has been 
found to be more common in women than in men [21-23], 
as it was in our study. In an elderly Iranian population, 
the prevalence of MetS ranged between 41.9% (IDF) and 
50.8% (NCEP) and it was higher in women than in men, 
with high concordance between the two definitions [24].
Data in the general population of men shows that 
the prevalence of HTGW is high (around 20%) and 
Table III. Characteristics of 155 male subjects with type 2 diabetes classified according to the two definitions of metabolic 
syndrome and the “hypertriglyceridemic waist” phenotype
Tabela III. Charakterystyka 155 mężczyzn chorujących na cukrzycę typu 2 w grupach wydzielonych na podstawie dwóch 
definicji zespołu metabolicznego i fenotypu “talii hipertriglicemicznej”
AHA/NHLBI definition IDF definition “Hypertriglyceridemic waist” phenotype
Subjects MetS No MetS MetS No MetS HTGW No HTGW
No. (%) 97 (62.58) 58 (37.42) 103 (66.45) 52 (33.55) 62 (40) 93 (60)
Age (years) 61.36 ± 9.85 60.83 ± 9.81 61.93 ± 9.86 59.63 ± 9.63 59.73 ± 10.15 62.12 ± 9.51
Duration of DM 
(years) 12.24 ± 8.12 10.36 ± 8.62 12.37 ± 8.97 9.88 ± 6.68 11.42 ± 8.16 11.61 ± 8.49
BMI [kg/m2] 28.68 ± 4.03** 24.89 ± 3.56 28.84 ± 3.73** 24.12 ± 3.48 29.33 ± 4.08** 25.88 ± 3.82
WC [cm] 102.15 ± 8.92** 92.21 ± 9.23 103.17 ± 7.19** 89.04 ± 8.76 103.82 ± 7.88** 94.84 ± 10.05
SBP [mm Hg] 141.55 ± 17.40** 129.83 ± 20.02 140.05 ± 17.62** 131.44 ± 21.08 138.55 ± 17.49 136.24 ± 20.33
DBP [mm Hg] 84.02 ± 10.74** 78.71 ± 9.89 84.13 ± 10.58** 77.88 ± 9.82 84.19 ± 10.13* 80.59 ± 10.91
TC [mmol/l] 6.08 ± 1.93* 5.55 ± 0.96 6.03 ± 1.82 5.57 ± 1.18 6.49 ± 2.13** 5.47 ± 1.07
HDL-C [mmol/l] 1.22 ± 0.45** 1.41 ± 0.30 1.26 ± 0.44* 1.36 ± 0.34 1.24 ± 0.49 1.32 ± 0.35
LDL-C [mmol/l] 3.40 ± 0.96 3.44 ± 0.86 3.42 ± 0.82 3.40 ± 1.09 3.49 ± 0.88 3.37 ± 0.94
TG [mmol/l] 3.66 ± 4.36** 1.40 ± 0.68 3.41 ± 4.25** 1.62 ± 1.31 4.55 ± 5.05** 1.66 ± 1.38
HbA1c (%) 8.02 ± 1.87* 7.45 ± 1.75 7.86 ± 1.82 7.70 ± 1.91 8.28 ± 1.97** 7.49 ± 1.69
FPG [mmol/l] 8.89 ± 3.45 8.08 ± 3.67 8.77 ± 3.38 8.23 ± 3.86 9.65 ± 3.56** 7.88 ± 3.37
PPG [mmol/l] 12.35 ± 3.66 11.65 ± 4.22 12.06 ± 3.61 12.15 ± 4.40 13.02 ± 3.67** 11.47 ± 3.91
AHA/NHLBI — American Heart Association/National Heart, Lung and Blood Institute; IDF — International Diabetes Federation; MetS — metabolic 
syndrome; HTGW — “hypertriglyceridemic waist”; BMI — body mass index; WC — waist circumference; SBP — systolic blood pressure; 
DBP — diastolic blood pressure; TC — total cholesterol; HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; 
TG — triglyceride; HbA1c — glycated haemoglobin A1c; FPG — fasting plasma glucose; PPG — postprandial glucose; Data are mean ± SD; 
*MetS vs. no MetS or HTGW vs. no HTGW p < 0.05; **MetS vs. no MetS or HTGW vs. no HTGW p < 0.01
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that it is associated with increased risk of CVD even 
in the absence of DM [25]. There are similarities in 
terms of the lipid disorders in diabetic patients and in 
non-diabetics with HTGW, above all in the lowering of 
the level of HDL cholesterol which bears elevated risk 
for CVD [26]. The prevalence of HTGW in the general 
population of women is lower than in men and is 
around 15% but the risk for CVD is also elevated as in 
men [27]. As it is with MetS, the presence of HTGW 
is almost two fold higher in the high risk populations 
such as diabetic patients. Our results, showing 40% 
of men and 43% of women having HTGW, are similar 
to that data.
Many studies have estimated the effect of the 
presence of MetS on the risk for CVD. Most show 
that the presence of MetS is an important risk factor 
for all the manifestations of CHD and its complica-
tions. We examined the relationship of the pres-
ence of MetS or HTGW and known risk factors for 
atherosclerosis (dyslipidemia) and blood glucose 
control in diabetic patients. It can be assumed that 
the presence of MetS increases risk for CVD, by 
among other things worsening dyslipidemia and 
blood glucose control.
In a study of 4,350 diabetic patients, those with 
MetS according to NCEP criteria had the highest risk 
for CHD, while the IDF definition of MetS did not 
show significance in predicting future cardiovascular 
events. The authors think that despite having hyperten-
sion and dyslipidemia, patients without central obesity 
will not be categorised as having metabolic syndrome 
using the IDF criteria. For those individuals who did 
not have central obesity, the application of the NCEP 
ATP III criteria identified a subgroup at even higher 
risk of CHD. Individuals in the NCEP-only group were 
thinner and had worse glycemic control, lipid profiles, 
renal function, and albuminuria, which all are known 
risk factors for CHD. By using individual cardiovascular 
risk factors in regression analysis, blood pressure and 
HDL cholesterol were identified as the strongest predic-
tors of CHD [12].
In the Strong Heart Study in diabetic patients, 
the presence of MetS according to the NCEP criteria 
was connected to the highest cardiovascular risk. The 
presence of MetS according to the IDF criteria was 
connected to a smaller risk, but that difference was not 
statistically significant [21]. These two results can be 
correlated with our findings that the presence of MetS 
according to the AHA/NHLBI criteria is connected 
to higher levels of cholesterol and LDL cholesterol. 
Similarly, in a prospective study of 750 subjects who 
underwent coronary angiography, the NCEP definition 
of MetS yielded a significantly higher risk of vascular 
events than did the IDF definition [11]. Another study 
has shown that the revised NCEP definition in males, 
and the IDF definition in females, are the strongest 
predictors of carotid atherosclerosis [28]. In a Chinese 
population, the presence of MetS according to the IDF 
definition was more strongly associated with CHD than 
the presence of MetS according to the NCEP definition, 
but the agreement of the two definitions was very high 
in this study [19].
On the other hand, there is data of the general pop-
ulation (not only diabetic patients) indicating that the 
definition proposed by the IDF may be more accurate 
in identifying individuals at very high cardiovascular 
risk compared to the NCEP-ATP III and NHLBI defi-
nitions. Greek authors showed the presence of MetS 
in 81.2% and 79.1% (by the NHLBI and IDF criteria, 
respectively) of patients with acute coronary syndrome 
(ACS), and in the final analysis found that presence 
of MetS according to IDF criteria was a significantly 
better predictor of ACS [29]. They assumed that the 
IDF definition would be more likely to have stronger 
discriminatory power than the other definitions in 
identifying future CHD events, because it emphasises 
WC, an established index of abdominal obesity which 
provides information not only for conventional risk 
factors but also for cardiometabolic risk profile among 
individuals [9, 10].
Similar results were found in a group of Japanese 
patients who underwent percutaneous coronary in-
tervention in which the prevalence of MetS was 36%, 
which is similar to the prevalence noted in previous 
studies of Western populations, highlighting the fact 
that the risk of MetS may not be different among vari-
ous ethnic groups, even though the definition of obesity 
varies according to ethnicity, as mentioned in the IDF 
definition of MetS [30]. In that study, patients with 
obesity, defined as BMI ≥ 25 kg/m2, have a higher risk 
of a subsequent cardiac event than patients with any 
other component of MetS, giving consequently a certain 
advantage to the IDF definition.
Our results correlate with data showing that 
in a population of diabetic patients, the use of the 
AHA/NHLBI definition has certain advantages since 
it better defines those with more dyslipidemia and 
consequently a higher risk for CVD.
A study comparing the ability of the three clini-
cal approaches (i.e. defining MetS by NCEP or IDF 
criteria or the hypertriglyceridemic waist phenotype) 
to identify individuals at increased cardiometabolic 
risk has shown that a large proportion of men with 
HTGW also met the NCEP-ATP III (82.7%) or IDF 
(89.2%) criteria. The Framingham risk score of men 
meeting any of the three screening tools criteria was 
higher, and was similar across the three approaches 
[4.2 (HTGW), 3.8 (NCEP) and 3.7 (IDF)]. The authors 
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concluded that HTGW may be as discriminatory as 
the NCEP-ATP III or the IDF criteria and could be 
used as an initial screening approach to identify 
individuals with deteriorated cardiometabolic risk 
markers [31].
In a study looking at a population of diabetic 
patients, the authors concluded that the “hypertrig-
lyceridemic waist” phenotype, an inexpensive and 
simple tool identifying subjects with metabolic syn-
drome features, is a significant marker of CHD mani-
festations occurring at an earlier age in those with 
glucose intolerance or type 2 diabetes [32]. HTGW 
is associated with increased coronary risk factors 
among women as for men [27]. HTGW is associated 
with a hostile lipid profile that includes higher levels 
of small, dense LDL cholesterol and decreased LDL 
particle size [33].
Our results show significant differences in a majority 
of studied risk factors when HTGW is present and it cor-
relates with most of the aforementioned data, but those 
differences are more present in men than in women. 
Therefore our results differ somewhat  compared to 
previous results.
Conclusions
Bearing in mind all the results reported in our pa-
tients, it can be concluded that metabolic syndrome is 
present in a large number of type 2 diabetic patients, 
with almost three quarters fulfilling both AHA/NHLBI 
and IDF criteria. Women have metabolic syndrome 
more often than men and that is the case using either 
definition. More than 40% of type 2 diabetic patients 
have a hypertriglyceridemic waist phenotype, equally 
among men and women. This number of patients 
is significantly smaller than those having metabolic 
syndrome.
In a population of diabetic patients, the use of 
the AHA/NHLBI definition has certain advantages 
since it better correlates with worse lipid profile and 
consequently with higher risk for cardiovascular 
diseases.
Determining “hypertriglyceridemic waist” pheno-
type in diabetic patients is a simple tool for identifying 
subjects with increased risk for cardiovascular diseases, 
especially in men in whom it identifies those with worse 
lipid profile and poor blood glucose control.
Because recent decades have seen steep rises in the 
prevalence of obesity and type 2 diabetes, it is very im-
portant to identify those with increased cardiovascular 
risk as soon as possible. Using a definition of metabolic 
syndrome or, even easier, determining a “hypertriglyc-
eridemic waist” phenotype gives the opportunity for 
early preventive intervention.
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